Skip to main content
Smart Investors Daily
DN

NYSE · DNA

Ginkgo Bioworks Holdings, Inc.

Healthcare · Biotechnology

$6.75

Down-$0.03 (-0.44%)

Updated Sep 12, 2026, 12:34 PM

SID Score

3.3/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
539.91M
P/E ratio
-1.62
Dividend yield
0.00%
52-week range
$5.37 – $17.58
Volume
932.66K
Avg. volume
1.4M

Price performance

DNA price history

1M range · 20 trading sessions · Daily adjusted prices

DNA closed at $6.75 after 20 trading sessions, down 0.59% for the selected period.

Last close
$6.75
Period change
-0.59%
Period low
$6.53
Period high
$7.71
Daily close
View OHLC price history
DNA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$6.80$6.83$6.52$6.75932.66K
Sep 10, 2026$6.72$6.85$6.59$6.78679.47K
Sep 9, 2026$6.83$6.93$6.72$6.79894.18K
Sep 8, 2026$7.00$7.06$6.75$6.941.08M
Sep 4, 2026$6.80$6.97$6.74$6.95656.66K
Sep 3, 2026$7.16$7.22$6.76$6.95860.36K
Sep 2, 2026$6.92$7.2986$6.77$7.031.27M
Sep 1, 2026$6.66$6.985$6.62$6.931.81M
Aug 31, 2026$6.90$6.96$6.67$6.811.21M
Aug 28, 2026$7.23$7.285$6.91$6.961.26M
Aug 27, 2026$7.34$7.43$7.17$7.26757.66K
Aug 26, 2026$7.33$7.47$7.19$7.23628.79K
Aug 25, 2026$6.94$7.63$6.86$7.541.68M
Aug 24, 2026$7.25$7.305$6.75$6.781.08M
Aug 21, 2026$7.09$7.42$6.82$7.401.44M
Aug 20, 2026$7.45$7.645$6.925$6.961.42M
Aug 19, 2026$6.98$7.7485$6.95$7.712.47M
Aug 18, 2026$6.72$6.875$6.47$6.531.12M
Aug 17, 2026$6.70$6.99$6.62$6.92690.13K
Aug 14, 2026$7.20$7.20$6.775$6.791.45M

Latest DNA news

The latest Smart Investors Daily articles mentioning DNA.

DNA research

Overview

Company profile and research snapshot.

Company profile

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
$9.00
Implied upside
Analysts
DNA recent ratings
DateFirmRatingTarget
Sep 4, 2026BTIGSell
Aug 7, 2026TD CowenHold
Mar 12, 2026BTIGSell
Jan 8, 2026TD CowenBuy
Aug 25, 2025BTIGSell
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.